A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
Part of paid clinical trials in Anaheim, California.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT05048719
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- LY3502970 — DRUGAdministered orally
- Dulaglutide — DRUGAdministered subcutaneously
- Placebo — DRUGAdministered orally
- Placebo — DRUGAdministered subcutaneously
Study Details
The main purpose of this study is to evaluate the efficacy and safety of LY3502970 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 30 weeks.
Key Dates
- Start date
- Sep 15, 2021
- Status verified
- Sep 2023
- Primary completion
- Sep 30, 2022
- Completion
- Sep 30, 2022
Study Design
- Enrollment
- 383 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: 3 milligrams (mg) LY3502970Participants received maintenance dose of 3 mg with dose escalation starting from 2 mg LY3502970 administered orally once daily (QD).
- Experimental: 12 mg LY3502970Participants received maintenance dose 12 mg with dose escalation starting from 2 mg, 6 mg and then 12 mg LY3502970 administered orally QD.
- Experimental: 24 mg LY3502970Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally QD.
- Experimental: 36 mg LY3502970 - 1Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
- Experimental: 36 mg LY3502970 - 2Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
- Experimental: 45 mg LY3502970 - 1Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
- Experimental: 45 mg LY3502970 - 2Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
- Active Comparator: 1.5 mg DulaglutideParticipants received 1.5 mg Dulaglutide administered subcutaneously (SC) once weekly (QW).
- Placebo Comparator: PlaceboParticipants received matching placebo.
Primary Outcome Measure
Change From Baseline in HbA1c in LY3502970 as Compared to Placebo [ Time Frame: Baseline, Week 26 ]
Locations (20)
Find similar trials in Anaheim, CA
By condition
By specialty
By research site
Anaheim Clinical Trials, LLC· Anaheim, CAVelocity Clinical Research, Huntington Park· Huntington Park, CAVelocity Clinical Research, Westlake· Los Angeles, CARancho Cucamonga Clinical Research· Rancho Cucamonga, CATouro University California· Vallejo, CANew West Physicians Clinical Research· Golden, CO
Related Studies
- Sleep and Glycemic Control in Type 2 Diabetes AdolescentsRecruiting · Children's Hospital of Philadelphia · Philadelphia, Pennsylvania
- Time Limited Eating in Adolescents With Type 2 Diabetes (KT2D)Recruiting · Children's Hospital Los Angeles · Los Angeles, California
- Role of Microvascular Insulin Resistance and Cardiorespiratory Fitness DiabetesRecruiting · University of Colorado, Denver · Aurora, Colorado
- Effectiveness and Safety of the RIGHTEST Continuous Glucose Monitoring System for Blood Glucose Management in Persons With Diabetes MellitusNot Yet Recruiting · Bionime Corporation · Guntersville, Alabama